Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway

KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorectal tumors. Oncogenic KRAS stimulates several pro-survival pathways, but it also triggers the trans-activation of pro-apoptotic genes. In our work, we show that G13D mutations of KRAS activate the MAPK...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Conti, Annalisa, Majorini, Maria Teresa, Elliott, Richard, Ashworth, Alan, Lord, Christopher J., Cancelliere, Carlotta, Bardelli, Alberto, Seneci, Pierfausto, Walczak, Henning, Delia, Domenico, Lecis, Daniele
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2015
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484434/
https://ncbi.nlm.nih.gov/pubmed/26028667
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge